Promomed Group's drugs are included in the new version for the prevention and treatment of COVID-19

25.02.2022

Medicines

On February 22, 2022, the Russian Ministry of Health approved the 15th version of the Interim Guidelines for the Prevention, Diagnosis and Treatment of new Coronavirus infection. The list of possible medications for the treatment of COVID-19 in adults includes 6 drugs, two of which are produced by Promomed Group of Companies — Esperavir® (molnupiravir) and Areplivir® (favipiravir) in two dosage forms. They have already proven themselves as effective agents in the treatment of coronavirus infection and covid-19 syndrome.


Complications and consequences of coronavirus infection are no less dangerous for patients. In this regard, Promomed Group pays great attention to the development and production of drugs aimed at complex therapy, focusing on solving global medical problems and saving lives. The company's anticoagulant portfolio already includes effective anticoagulants Enoparin® and Thrombophorse® forte, Radamine® RNA-based Viro and a number of antibiotics. All these medicines are also included in the current recommendations of the Ministry of Health of the Russian Federation, published on the official website.

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office